The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The importance of educating patients about adverse effects of treatment
Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK stresses the importance of educating patients about adverse effects of therapy for chronic lymphocytic leukemia (CLL) and follicular lymphoma. For example diarrhea and colitis can occur long after treatment with idelalisib according to Dr Davies. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
